<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612768</url>
  </required_header>
  <id_info>
    <org_study_id>Mekos 07 2P1/2 401</org_study_id>
    <secondary_id>20071738</secondary_id>
    <nct_id>NCT00612768</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations</brief_title>
  <official_title>Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allerderm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allerderm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open, prospective, multi-center study to evaluate the bioequivalence of povidone (PVP)
      formulations of 2 T.R.U.E. TEST allergens: fragrance mix and thimerosal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bioequivalence will be determined in 40 adult subjects (20 per allergen), who have a clinical
      history of contact dermatitis and have tested positive to fragrance mix or thimerosal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of Bioequivalence: Concordance</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Percent agreement between T.R.U.E. Test allergen in PVP vs HPC is based on a positive test response during at least one post application visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agreement Between TRUE Test Allergen and Reference Allergen</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Sensitivity: Agreement between positive results for the test and reference allergen Specificity: Agreement between negative results for the test and reference allergen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Irritation, Adhesion, Itching/Burning</measure>
    <time_frame>Visit 2: 48 hours after patch application</time_frame>
    <description>Frequency of tape-induced irritation at the test site, incomplete panel adhesion and subject-reported sensations of itching or burning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Late and Persistent Reactions</measure>
    <time_frame>Day 2 (48 hours after application) through Day 21</time_frame>
    <description>Late reactions occur 7-10 days after patch application Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Dermatitis, Contact</condition>
  <arm_group>
    <arm_group_label>T.R.U.E. Test allergens Fragrance Mix and Thimerosol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concordance (agreement) between positive patch reactions to
fragrance mix (0.43 mg/cm2) in polyvinylpyrrolidone (PVP) vs fragrance mix (0.43 mg/cm2) in hydroxypropylcellulose (HPC)
thimerosol (0.008 mg/cm2) in polyvinylpyrrolidone (PVP) vs thimerosol (0.008 mg/cm2) in hydroxypropylcellulose (HPC)
fragrance mix T.R.U.E. Test allergen vs fragrance mix reference allergen (petrolatum)
thimerosol T.R.U.E. Test allergen vs thimerosol reference allergen (petrolatum)
will be measured</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TRUE Test allergens Fragrance Mix and Thimerosol</intervention_name>
    <description>Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose
Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone
Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin
Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin
Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours.</description>
    <arm_group_label>T.R.U.E. Test allergens Fragrance Mix and Thimerosol</arm_group_label>
    <other_name>T.R.U.E. TEST Skin Patch Test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current or previous symptoms and/or history consistent with allergic contact
             dermatitis, and positive patch test (within the past 5 years) to fragrance mix AND/OR
             thimerosal.

          -  All subjects must be adults (18 years of age or older) and otherwise in good health.

          -  Pre-menopausal female subjects must consent to a urine pregnancy test; results must be
             negative for study inclusion.

          -  Informed consent must be signed and understood by each subject, and consistent with
             all institutional, local and national regulations.

        Exclusion Criteria:

          -  Subjects unable to meet inclusion requirements.

          -  Women who are breastfeeding or pregnant.

          -  Topical treatment during the last 7 days with corticosteroids or other
             immunosuppressive agents on or near the test area.

          -  Systemic treatment during the last 7 days with corticosteroids (equivalent to &gt; 10 mg
             prednisone) or other immunosuppressive agents.

          -  Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks.

          -  Acute dermatitis outbreak or dermatitis on or near the test area on the back.

          -  Subjects unable to comply with patch test study requirements including multiple return
             visits and activity restrictions (e.g., protecting test panels from excess moisture
             due to showering or vigorous activity).

          -  Subject participation in clinical trials of investigational drugs, treatments, or
             devices, other than T.R.U.E. TEST, during this study or 3 weeks prior to inclusion in
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists PSC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luz Fonacier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald V. Belsito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Dermatology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerri Hoskyn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>River City Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>River City Dermatology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Dermatology Associates</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists PSC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-1864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2008</study_first_posted>
  <results_first_submitted>February 26, 2013</results_first_submitted>
  <results_first_submitted_qc>April 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2018</results_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Thimerosal</keyword>
  <keyword>Fragrance Mix</keyword>
  <keyword>PVP formulation</keyword>
  <keyword>Contact dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 4 centers in the United States. The first subject was enrolled on Jan 2 2008 and the study completed on Dec 12 2008.</recruitment_details>
      <pre_assignment_details>No subject was excluded from the trial following enrollment but before assignment to a group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sensitive Subjects</title>
          <description>All subjects recruited to this study were to have had previous positive patch test results to one of the allergens tested on the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sensitive Subjects</title>
          <description>Subjects with a clinical history and positive patch test (current or previous) to either fragrance mix or thimerosal. Study subjects must be otherwise healthy and fulfill entry criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.4" spread="16.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Analysis of Bioequivalence: Concordance</title>
        <description>Percent agreement between T.R.U.E. Test allergen in PVP vs HPC is based on a positive test response during at least one post application visit</description>
        <time_frame>Up to 21 days</time_frame>
        <population>The data from 50 subjects enrolled in the study was analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Fragrance Mix</title>
            <description>Percent agreement between T.R.U.E. Test allergen in PVP vs HPC</description>
          </group>
          <group group_id="O2">
            <title>Thimerosol</title>
            <description>Percent agreement between T.R.U.E. Test allergen in PVP vs HPC</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Bioequivalence: Concordance</title>
          <description>Percent agreement between T.R.U.E. Test allergen in PVP vs HPC is based on a positive test response during at least one post application visit</description>
          <population>The data from 50 subjects enrolled in the study was analyzed</population>
          <units>percentage of agreement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="61.8" upper_limit="86.9"/>
                    <measurement group_id="O2" value="98.0" lower_limit="89.4" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Agreement Between TRUE Test Allergen and Reference Allergen</title>
        <description>Sensitivity: Agreement between positive results for the test and reference allergen Specificity: Agreement between negative results for the test and reference allergen</description>
        <time_frame>Up to 21 days</time_frame>
        <population>The data from all enrolled subjects was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity: Fragrance Mix in HPC</title>
            <description>Agreement between positive results for the test and reference allergen</description>
          </group>
          <group group_id="O2">
            <title>Sensitivity: Fragrance Mix in PVP</title>
            <description>Agreement between positive results for the test and reference allergen</description>
          </group>
          <group group_id="O3">
            <title>Sensitivity: Thimerosal in HPC</title>
            <description>Agreement between positive results for the test and reference allergen</description>
          </group>
          <group group_id="O4">
            <title>Sensitivity: Thimerosol in PVP</title>
            <description>Agreement between positive results for the test and reference allergen</description>
          </group>
          <group group_id="O5">
            <title>Specificity: Fragrance Mix in HPC</title>
            <description>Agreement between negative results for the test and reference allergen</description>
          </group>
          <group group_id="O6">
            <title>Specificity: Fragrance Mix in PVP</title>
            <description>Agreement between negative results for the test and reference allergen</description>
          </group>
          <group group_id="O7">
            <title>Specificity: Thimerosal in HPC</title>
            <description>Agreement between negative results for the test and reference allergen</description>
          </group>
          <group group_id="O8">
            <title>Specificity: Thimerosal in PVP</title>
            <description>Agreement between negative results for the test and reference allergen</description>
          </group>
        </group_list>
        <measure>
          <title>Agreement Between TRUE Test Allergen and Reference Allergen</title>
          <description>Sensitivity: Agreement between positive results for the test and reference allergen Specificity: Agreement between negative results for the test and reference allergen</description>
          <population>The data from all enrolled subjects was analyzed.</population>
          <units>percentage of agreement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="20.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="59.1" lower_limit="36.4" upper_limit="79.3"/>
                    <measurement group_id="O3" value="61.5" lower_limit="40.6" upper_limit="79.8"/>
                    <measurement group_id="O4" value="65.4" lower_limit="44.3" upper_limit="82.8"/>
                    <measurement group_id="O5" value="92.9" lower_limit="76.5" upper_limit="99.1"/>
                    <measurement group_id="O6" value="100" lower_limit="87.7" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="85.8" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="85.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Irritation, Adhesion, Itching/Burning</title>
        <description>Frequency of tape-induced irritation at the test site, incomplete panel adhesion and subject-reported sensations of itching or burning.</description>
        <time_frame>Visit 2: 48 hours after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tape Irritation: TRUE Test Panel</title>
            <description>Percentage of participants who exhibited tape-induced irritation at visit 2.</description>
          </group>
          <group group_id="O2">
            <title>Incomplete Panel Adhesion: TRUE Test</title>
            <description>Percentage of participants whose panels were not 100% adhered at visit 2.</description>
          </group>
          <group group_id="O3">
            <title>Incomplete Panel Adhesion: Reference Allergen</title>
            <description>Percentage of participants whose panels were not 100% adhered at visit 2.</description>
          </group>
          <group group_id="O4">
            <title>Itching and Burning</title>
            <description>Percentage of participants who reported patch related itching and/or burning at visit 2</description>
          </group>
        </group_list>
        <measure>
          <title>Irritation, Adhesion, Itching/Burning</title>
          <description>Frequency of tape-induced irritation at the test site, incomplete panel adhesion and subject-reported sensations of itching or burning.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Late and Persistent Reactions</title>
        <description>Late reactions occur 7-10 days after patch application Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
        <time_frame>Day 2 (48 hours after application) through Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Late Reactions: Fragrance Mix in HPC</title>
            <description>Late reactions occur 7-10 days after patch application</description>
          </group>
          <group group_id="O2">
            <title>Late Reactions: Fragrance Mix in PVP</title>
            <description>Late reactions occur 7-10 days after patch application</description>
          </group>
          <group group_id="O3">
            <title>Late Reactions: Thimerosal in HPC</title>
            <description>Late reactions occur 7-10 days after patch application</description>
          </group>
          <group group_id="O4">
            <title>Late Reactions: Thimerosol in PVP</title>
            <description>Late reactions occur 7-10 days after patch application</description>
          </group>
          <group group_id="O5">
            <title>Persistent Reactions: Fragrance Mix in HPC</title>
            <description>Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
          </group>
          <group group_id="O6">
            <title>Persistent Reactions: Fragrance Mix in PVP</title>
            <description>Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
          </group>
          <group group_id="O7">
            <title>Persistent Reactions: Thimerosal in HPC</title>
            <description>Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
          </group>
          <group group_id="O8">
            <title>Persistent Reactions: Thimerosal in PVP</title>
            <description>Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Late and Persistent Reactions</title>
          <description>Late reactions occur 7-10 days after patch application Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
          <units>percentage of subjects with reactions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0-21</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sensitives</title>
          <description>subjects per allergen with a clinical history and positive patch test (current or previous) to either fragrance mix or thimerosal. Study subjects must be otherwise healthy and fulfill entry criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Right femoral sheath placed secondary to tronsientischemic attack/carotid stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Itching and burning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Itching on/around site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Reports burning sensation, she thinks it might be due to the tape</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Itching at positive patch sites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathy Shannon</name_or_title>
      <organization>SmartPractice</organization>
      <phone>602-225-0595 ext 7208</phone>
      <email>kshannon@smarthealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

